Impact of lower achieved blood pressure on outcomes in hypertensive patients
- 1 April 2012
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 30 (4), 802-810
- https://doi.org/10.1097/hjh.0b013e3283516499
Abstract
Hypertensive patients with ECG left-ventricular hypertrophy (LVH) are at increased risk of cardiovascular morbidity and mortality, and regression of ECG LVH is associated with improved cardiovascular outcomes. Although tighter control of systolic blood pressure (SBP) has been associated with a lower rate of ECG LVH, whether tighter vs. standard control of SBP is associated with greater reduction of cardiovascular risk is unclear. Risk of stroke, myocardial infarction (MI), cardiovascular death, the composite endpoint of these events and all-cause mortality were examined in relation to in-treatment achieved SBP in 9193 hypertensive patients with ECG LVH randomly assigned to losartan or atenolol-based treatment. Patients with in-treatment SBP 130 mmHg or less (lowest quintile at last measurement) and SBP between 131 and 141 mmHg were compared with patients with in-treatment SBP at least 142 mmHg (median SBP at last measurement). In univariate analyses, compared with in-treatment SBP at least 142 mmHg, in-treatment SBP between 131 and 141 mmHg entered as a time-varying covariate identified patients with significantly lower risk of all events. In contrast, patients with SBP 130 mmHg or less had less reduction in MI, stroke and composite endpoint and no significant decrease in cardiovascular or all-cause mortality. In multivariate Cox analyses adjusting for baseline risk factors and randomized treatment as standard covariates and in-treatment diastolic BP, heart rate and Cornell product LVH as time-varying covariates, an in-treatment achieved SBP of 131 to 141 mmHg remained associated with a significantly decreased risk of MI, stroke and the LIFE composite endpoint. In contrast, patients who achieved a SBP 130 mmHg or less had no significant reduction in risk of MI, stroke or composite endpoint, had a trend to increased cardiovascular mortality [hazard ratio 1.32, 95% confidence interval (CI) 0.97-1.81, P = 0.078] and a statistically significant 37% increased risk of death from any cause (hazard ratio 1.37, 95% CI 1.10-1.71, P = 0.005). Achieved SBP 130 mmHg or less is not associated with lower cardiovascular risk than SBP of 131 to 141 mmHg and is associated with a significantly increased risk of death and trend towards increased cardiovascular mortality. These findings support the need for randomized evaluation of treatment to more aggressive vs. conventional SBP targets.Keywords
This publication has 38 references indexed in Scilit:
- Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery DiseaseJama-Journal Of The American Medical Association, 2010
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes MellitusThe New England Journal of Medicine, 2010
- Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trialThe Lancet, 2009
- Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertensionJournal of Hypertension, 2009
- Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS)Hypertension Research, 2008
- 2007 Guidelines for the Management of Arterial HypertensionJournal of Hypertension, 2007
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJama-Journal Of The American Medical Association, 2003
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002
- Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre studyThe Lancet, 2000
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trialThe Lancet, 1998